INDIANAPOLIS – Governor Mitch Daniels joined executives from Roche Diagnostics Corporation today to announce the company’s plans to invest in its operations here, creating up to 100 jobs by 2017.
The company, a leader in in-vitro diagnostics, will invest $300 million over the next 10 years at its North American headquarters on the northeast side of Indianapolis. The capital investments, which will include the refurbishing of existing buildings, purchasing of manufacturing equipment for new diabetes care test strips and upgrading of information technology equipment, will support the company’s growing diagnostics and diabetes care businesses. Roche Diagnostics will begin its campus transformation this fall with the construction of a new commercial education center where approximately 1,500 customers from across the nation will be trained annually.
“From a one-man, start-up company in a garage to a global industry leader in less than 50 years illustrates the power of Hoosier ingenuity and entrepreneurship,” said Daniels. “Roche’s continued growth has shown that Indiana is the epicenter for the life sciences industry and the premier state for growing an innovative business.” Roche Diagnostics has been part of the Indianapolis landscape since 1964 when it was founded as Bio-Dynamics and later acquired by Boehringer Mannheim Corporation in 1974. Roche acquired Boehringer Mannheim in 1998 and within three years became a world leader in diagnostics. Today, the company employs nearly 3,000 Hoosiers and more than 4,200 associates nationwide. “As the leader in the in-vitro diagnostics industry, we’re proud to be a part of the growing life sciences movement in central Indiana,” said Jack Phillips, president and chief executive officer of Roche Diagnostics. “We appreciate the partnership from the city and state as we look to increase jobs and enhance our Indianapolis campus facilities. The bottom line is we’re here to stay and committed to being the best place to work in Indiana.”
As the North American headquarters for Roche Diagnostics and Roche Diabetes Care, the 160-acre Indianapolis campus is home to research and development, manufacturing, distribution, information technology, shared services and administrative operations. About two-thirds of the workforce supports sales and marketing efforts. The campus also is a major production site of test strips for ACCU-CHEK® products, manufacturing about 2 billion strips annually.
The Indiana Economic Development Corporation offered Roche Diagnostics Operations, Inc. up to $2,000,000 in conditional tax credits and up to $300,000 in training grants based on the company’s job creation plans. These tax credits are performance-based, meaning until Hoosiers are hired, the company is not eligible to claim incentives. The city of Indianapolis will consider additional property tax abatement at the request of Develop Indy. “Indianapolis’ stable tax climate and pro-growth economic environment offers businesses of all types opportunity to thrive,” said Indianapolis Mayor Greg Ballard. “We are thrilled with this investment by Roche and are proud to have corporate partners who share our commitment to building a community that is open for business, providing quality jobs for our talented workforce.” Roche Diagnostics’ continued growth in Indianapolis builds on the Hoosier State’s $44 billion global life sciences sector. Last year, The Wall Street Journal cited Indianapolis as "one of the hottest spots for starting a new business" and a national hub for the life sciences industry. Indiana has added more than 8,800 jobs in the life sciences industry in recent years and today some 854 medical-device companies, drug manufacturers and research labs call the Hoosier State home.
For more information:
Last updated on: 07/08/2012
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.